Keyphrases
Inflammatory Bowel Disease
100%
Crohn's Disease
64%
Infliximab
62%
Vedolizumab
40%
Adalimumab
28%
Anti-tumor Necrosis Factor (anti-TNF)
26%
Anti-drug Antibodies
25%
Ulcerative Colitis
21%
Loss of Response
19%
Clinical Remission
19%
Clinical Response
18%
Trough Level
17%
Immunogenicity
17%
Infliximab Levels
17%
Antibodies to Infliximab
17%
Drug Levels
17%
Real-world Experience
15%
Anti-infliximab Antibodies
14%
Infliximab Therapy
14%
Confidence Interval
13%
Pharmacokinetics
12%
Israeli
12%
Ustekinumab
10%
Odds Ratio
10%
Immunomodulator
9%
Treatment Failure
9%
Tumor Necrosis Factor-α
9%
Terminal Ileum
9%
Active Ulcerative Colitis
9%
Thiopurines
8%
Anti-adalimumab Antibodies
8%
Inflammation
8%
Infliximab Trough Level
8%
Retrospective Cohort Study
7%
Antibody Level
7%
Adverse Events
7%
Emergency Department
7%
Mucosal Healing
7%
Antibody Formation
7%
Remission
7%
Maintenance Treatment
7%
Remission Induction
6%
Drug Concentration
6%
Disease-related
6%
Ulcerative Colitis Patient
6%
Hospitalized Patients
6%
Biological Therapy
6%
Inflammatory Bowel
6%
Pooled Analysis
6%
Tumour Necrosis Factor Inhibitor (TNFi)
6%
Pharmacology, Toxicology and Pharmaceutical Science
Inflammatory Bowel Disease
79%
Infliximab
60%
Crohn's Disease
46%
Ulcerative Colitis
33%
Remission
29%
Vedolizumab
23%
Tumor Necrosis Factor
22%
Adalimumab
21%
Trough Level
18%
Cohort Study
11%
Ustekinumab
10%
Immunogenicity
10%
Biological Product
10%
Tumor Necrosis Factor Inhibitor
10%
Pharmacokinetics
8%
Mercaptopurine
8%
Inflammation
7%
Drug Concentration
6%
Ileum
6%
Retrospective Study
6%
Disease
5%
Combination Therapy
5%
Adverse Event
5%
Calgranulin
5%
Medicine and Dentistry
Inflammatory Bowel Disease
44%
Crohn's Disease
36%
Infliximab
30%
Vedolizumab
28%
Ulcerative Colitis
22%
Trough Level
19%
Patient with Inflammatory Bowel Disease
16%
Patient with Crohn's Disease
12%
Retrospective Cohort Study
10%
Adalimumab
10%
TNF Inhibitor
8%
Terminal Ileum
8%
Maintenance Therapy
8%
Odds Ratio
8%
Retrospective Study
7%
Tumor Necrosis Factor
7%
Emergency Department
7%
Biological Product
6%
Infusion
6%
Biological Therapy
6%
Infection
5%
Cohort Analysis
5%
Adverse Event
5%